A single arm, phase 2 study of amivantamab, lazertinib and pemetrexed for first-line treatment of recurrent / metastatic non-small cell lung cancers (NSCLCs) with EGFR mutations
Type of Study: Clinical Trial
Sponsor / Support: LACOG, Janssen
Primary Objectives: To evaluate the 18-month progression-free survival (PFS) rate of amivantamab, lazertinib and pemetrexed for first-line treatment of recurrent / metastatic non-small cell lung cancers (NSCLCs) with EGFR mutations.
Design: Interventional, single-arm, phase II trial
Sample Size: 49 patients.
Principal Investigator: William Nassib William Junior
Countries LATAM: Brazil
Clinicaltrials.gov Identifier: NCT05299125
The study is open to patients participation in the following research sites:
Ongoing studies
Breast
GBECAM 0115 – AMAZONA III
LACOG 0115 – LORELEI
LACOG 0221 – BRAVE
LACOG 0413 – Male Breast Cancer
LACOG 0419 – NEOSAMBA
LACOG 0615 – LATINABreast
LACOG 0715 – PALLAS
LACOG 2118 – ALEXANDRA/IMpassion 030
Gastrointestinal
LACOG 0119
LACOG 0222 – GASPAR
LACOG 0421 – ACTION HIV
LACOG/GTG 1318 – Anal Registry
Genitourinary
LACOG 0121 – PET-PSMA
LACOG 0217 – IRONMAN
LACOG 0218 – Hercules
LACOG 0519 – PEACE III
LACOG 0620 – ExBAT
LACOG 1120 – RENAL REGISTRY
LACOG 1818 – Prostate Cancer Registry
LACOG 2018 – Foundation Penile
Gynecological
LACOG 0820 – EVITA LATAM
LACOG 0920 – Senticol III
LACOG 1018 – PALBO in Ovarian Cancer
LACOG 1220 – CONOR
Head and Neck
LACOG 0319
LACOG 0720 – SMART-KEY
Lung
LACOG 0116 – LATINO LUNG
LACOG 0118 – RELANCE
LACOG 0120 – EAP durva lung cancer
LACOG 0821
LACOG 1918
LACOG 2218 – PACIFIC BRAZIL
Closed studies
Breast
LACOG 0111 – MGH
LACOG 0312 – METASTATIC BC
LACOG 0414
LACOG 0801 – GLICO
Genitourinary
LACOG 0415 – APA in Prostate Cancer
LACOG 0515 – Testicular Registry
LACOG 1518 – Bladder Cancer Registry
Gynecological
LACOG 0215 – EVITA
Head and Neck
LACOG 0318 – Induction
Lung
LACOG 0211 – ALK
LACOG 0417 – CNS MTX
LACOG 0618
Parsimony
Neuro
LACOG 0619
Other studies
LACOG 0213 – AUGMENT
LACOG 0214 – FINEP